| Popis: |
Elderly and type 2 diabetes mellitus (T2DM) patients with stable coronary artery disease (CAD) have increased risk of atherothrombotic events despite recommended secondary prevention therapy. High platelet reactivity drives this risk. Novel approaches to antiplatelet therapy are needed. Objectives: To: determine the effect of age and T2DM on blood thrombogenicity and response to dual antiplatelet therapy in stable CAD assess the effect of changes in platelet count on thrombus quantity and quality with Rafigrelide Methods: Study 1: Patients with stable CAD, 4 groups: age < 75 non-DM, age≥75 T2DM, age≥75 non-DM and age |
